Price transparency is the one thing that separates useful telehealth from a billing headache. Most GLP-1 platforms bury their real cost behind monthly program fees, separate pharmacy charges, or insurance-only pricing. The eight programs below charge you for medication, not membership. No recurring subscription to a dashboard you never open.
1. HealthRX
Compounded semaglutide opens at $99 per month. Compounded tirzepatide starts at $149. Those are flat, upfront numbers, no separate platform fee stacked on top.
Your intake form goes to a US board-certified physician for review, typically returned within about 24 hours. If approved, medication ships overnight at no extra cost to all 50 states. The compounding pharmacy is Manifest Pharmacy in Greer, South Carolina, a 503A facility operating under USP-797 standards with lot-tracked production. HealthRX holds LegitScript certification (cert 50087439), which requires independent review of pharmacy and prescribing practices.
The clinical trials HealthRX cites for context: tirzepatide at approximately 21% average body weight reduction at 72 weeks (SURMOUNT-1), semaglutide at approximately 15% at 68 weeks (STEP 1). These are trial results on branded drugs, not claims about compounded versions.
Best for: Cash-pay patients who want low entry pricing, fast shipping, and a named, verifiable pharmacy.
Honest caveat: Compounded medications are not FDA-approved. Verify your state’s telehealth prescribing rules before starting.
2. FormBlends
FormBlends runs a physician-overseen compounded GLP-1 program dispensed through an FDA-registered 503A compounding pharmacy. The standout detail is published purity testing per product: HPLC purity percentages, mass spec identity confirmation, and endotoxin and sterility results are posted with named numbers, not just claimed.
Semaglutide is priced at roughly $299 per vial, tirzepatide at roughly $349. Higher than HealthRX’s entry pricing, full stop. FormBlends also carries a wider catalog of compounded peptides covering recovery, longevity, and cognitive categories under the same clinician model, which almost no GLP-1-only telehealth brand touches. Ships to 47 states.
Best for: Anyone who wants documented batch-level purity data, or who wants GLP-1 therapy alongside other prescription peptides from one provider.
Honest caveat: Per-vial pricing is meaningfully higher than several competitors. The 47-state reach excludes a few markets.
3. Mochi Health
Mochi puts board-certified obesity-medicine physicians in the prescribing chair, not general practitioners. Compounded semaglutide is around $99 per month, tirzepatide around $199. The monitoring is heavier than most cash-pay options. That is either a feature or friction depending on how much hand-holding you want.
Best for: Patients who want obesity-specialist oversight and don’t mind more frequent check-ins.
Con: Tirzepatide pricing is higher than a few competitors at the same clinical tier.
4. Henry Meds
Henry Meds ships compounded GLP-1 medications in 24 to 72 hours. First-month pricing runs roughly $179 to $249 cash. The platform is lighter on lifestyle coaching than Mochi or Calibrate, which keeps overhead low and speed high.
Best for: People who already have a diet and exercise plan and just want medication fast without sitting through a coaching curriculum.
Con: Less structured monitoring may not suit patients who are new to injectable weight-loss medication.
5. Eden
Eden’s compounded semaglutide comes in at about $149 per month cash. Simple intake, physician review, and dispensing without a membership layer. The website is straightforward and pricing is easy to find.
Best for: Budget-focused patients who want a clean, no-extras experience closer to HealthRX’s price tier.
Con: Less publicly available information about compounding pharmacy specifics compared to providers who name their facility outright.
6. MEDVi
MEDVi charges roughly $179 for the first month of compounded treatment with no long-term contracts. Month-to-month structure means you are not locked in. The program is relatively new to the space compared to Hims & Hers or Ro, so the track record is shorter.
Best for: Patients who want a no-contract starting point without committing to a year-long program.
Con: Newer brand, so less publicly available patient experience data to draw from.
7. Hims & Hers
After the March 2026 Novo Nordisk settlement, Hims & Hers moved away from compounded GLP-1 products. Branded Wegovy is now around $299 per month through the platform, oral semaglutide around $249, and Zepbound around $399. With insurance plus a savings card, some patients pay close to nothing.
Best for: Patients with insurance coverage who want branded FDA-approved medication through a well-known platform.
Con: Cash-pay pricing is significantly higher than compounded alternatives. No compounded option currently available.
8. PlushCare
PlushCare’s membership is $19.99 per month, which technically puts it in membership territory, but it’s low enough to list here for context. Same-day provider visits are available, branded medications are covered, and the platform accepts insurance. Meds billed separately.
Best for: Insured patients who want fast branded prescription access and don’t mind a small monthly platform fee.
Con: Medication costs on top of membership can add up quickly without solid insurance coverage.
A Note on Compounded Medications
The FDA issued warning letters to more than 30 telehealth and compounding firms in early 2026. Compounded GLP-1 drugs are not FDA-approved and are not equivalent to branded products. Ask any provider for their pharmacy’s 503A registration details and any available testing documentation before ordering.
Common Questions
Is a no-membership GLP-1 program actually cheaper over six months than a subscription platform?
Usually yes, but not always. Subscription platforms sometimes bundle coaching, labs, or provider visits into their fee, which can offset the monthly cost if you use those services. For medication-only patients, no-membership programs like HealthRX at $99 per month or Eden at $149 will almost always cost less over a six-month stretch than platforms charging a separate program fee on top.
How do you verify that a compounding pharmacy used by one of these programs is legitimate?
Ask for the pharmacy’s 503A registration number and look it up in the FDA’s database of registered facilities. HealthRX names Manifest Pharmacy in Greer, South Carolina outright, which makes this easy. FormBlends publishes batch-level HPLC and sterility data. If a provider refuses to name their pharmacy, that is a meaningful red flag.
Can you switch between programs, say from Eden to HealthRX, without starting over clinically?
Yes, in most cases. These are month-to-month programs with no contracts, so you can stop one and start another after your current supply runs out. Your new provider will run their own intake and may ask for prior medical records or dosing history. There is no formal transfer process between competing telehealth platforms.
After Hims & Hers dropped compounded GLP-1s in 2026, what are the best remaining options for patients who want branded medication without insurance?
Hims & Hers still offers branded Wegovy at around $299 and Zepbound at around $399 per month. PlushCare can prescribe branded options too, though its $19.99 membership adds to the total. For most uninsured cash-pay patients, compounded programs at $99 to $199 per month remain the only genuinely affordable path.
Does FormBlends’ higher per-vial price reflect better quality, or just a different business model?
Partly both. FormBlends publishes more detailed third-party testing documentation than most competitors, which adds real cost. The wider peptide catalog also reflects a different target customer: someone managing multiple compounded protocols, not just weight loss. Whether the purity data justifies paying $299 versus $99 depends entirely on how much documentation matters to you personally.
Sources
- FDA: 503A Compounding Pharmacy Regulation, fda.gov
- SURMOUNT-1 trial (tirzepatide): *New England Journal of Medicine*, 2022, Jastreboff et al.
- STEP 1 trial (semaglutide): *New England Journal of Medicine*, 2021, Wilding et al.
- LegitScript Healthcare Merchant Certification program, legitscript.com
- Novo Nordisk settlement reporting, March 2026, Reuters and STAT News
